Eyepoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Here's Why

Key Points

• EyePoint shares opened sharply higher at $6.04 versus a prior close of $5.47, later trading near $5.97 on volume of about 1.78 million shares.
• Duravyu failed to meet the primary endpoint in a Phase 3 head-to-head wet AMD trial, causing an earlier roughly 70% selloff and raising significant approval and commercial concerns. Management argued that unrelated vision loss in nine patients may have distorted the results and highlighted favorable secondary endpoints.
• The company’s outlook remains mixed: LUCIA Phase 3 results are expected in the fourth quarter of 2026, while analysts range from bullish—with Citigroup maintaining a $17 target—to cautious, with RBC and Chardan assigning $5 targets and the overall consensus rating at Hold.

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $5.47, but opened at $6.04. Eyepoint Pharmaceuticals shares last traded at $5.97, with a volume of 1,783,505 shares.

Trending Headlines about Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: Management said the LUGANO Phase 3 failure in wet age-related macular degeneration may have been distorted by nine patients—about 4% of the study—who experienced vision loss unrelated to wet AMD. EyePoint also emphasized favorable secondary endpoints, including lower treatment burden and durable disease control. EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
• Positive Sentiment: The LUCIA Phase 3 trial remains a key potential catalyst, with results expected in the fourth quarter of 2026. A positive outcome could revive confidence in the Duravyu program and support a recovery in EYPT shares. EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
• Positive Sentiment: Citigroup maintained a buy rating and a $17 price target, implying substantial upside if EyePoint can overcome the clinical setback. Options activity was also elevated, with traders purchasing approximately 3,011 call contracts, suggesting some speculative interest in a rebound.
• Neutral Sentiment: Jefferies retained a buy rating but reduced its target to $8, while JPMorgan reaffirmed a neutral rating. These views indicate that analysts see potential value but have materially lowered expectations after the trial result.
• Negative Sentiment: Duravyu missed the primary endpoint in its head-to-head Phase 3 wet AMD study, triggering a roughly 70% collapse and raising significant uncertainty about the drug’s approval and commercial prospects. EyePoint Is Down After DURAVYU Misses Phase 3 Endpoint
• Negative Sentiment: Several firms became more cautious: RBC downgraded EYPT to hold, Chardan cut its rating to neutral, and Cantor Fitzgerald lowered its rating to neutral. RBC and Chardan both cited $5 price targets, signaling additional downside risk.

Analyst Ratings Changes

Several research firms have recently weighed in on EYPT. Royal Bank Of Canada reissued a "sector perform" rating and set a $5.00 price target on shares of Eyepoint Pharmaceuticals in a report on Tuesday. Stifel Nicolaus assumed coverage on Eyepoint Pharmaceuticals in a report on Thursday, July 16th. They issued a "buy" rating and a $40.00 price objective for the company. JPMorgan Chase & Co. reissued a "neutral" rating on shares of Eyepoint Pharmaceuticals in a report on Monday. Citigroup dropped their target price on Eyepoint Pharmaceuticals to $17.00 and set a "buy" rating on the stock in a research report on Tuesday. Finally, Weiss Ratings downgraded Eyepoint Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $28.11.

Eyepoint Pharmaceuticals Price Performance

The business has a 50-day simple moving average of $12.97 and a 200 day simple moving average of $13.55. The firm has a market cap of $521.05 million, a PE ratio of -1.61 and a beta of 1.76.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.08). Eyepoint Pharmaceuticals had a negative return on equity of 135.81% and a negative net margin of 10,994.73%.The firm had revenue of $0.51 million during the quarter, compared to analysts' expectations of $0.45 million. On average, equities analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -3.6 earnings per share for the current fiscal year.

Institutional Trading of Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Suvretta Capital Management LLC boosted its holdings in Eyepoint Pharmaceuticals by 26.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company's stock worth $143,012,000 after buying an additional 1,634,970 shares during the period. Adage Capital Partners GP L.L.C. raised its holdings in Eyepoint Pharmaceuticals by 9.7% during the second quarter. Adage Capital Partners GP L.L.C. now owns 6,800,000 shares of the company's stock valued at $63,988,000 after acquiring an additional 600,000 shares during the period. Federated Hermes Inc. lifted its position in shares of Eyepoint Pharmaceuticals by 36.3% in the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company's stock valued at $109,938,000 after acquiring an additional 1,601,101 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Eyepoint Pharmaceuticals by 19.3% in the fourth quarter. Franklin Resources Inc. now owns 4,976,915 shares of the company's stock valued at $90,928,000 after acquiring an additional 805,031 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Eyepoint Pharmaceuticals by 27.1% in the fourth quarter. Vanguard Group Inc. now owns 4,822,139 shares of the company's stock worth $88,100,000 after acquiring an additional 1,027,623 shares during the period. 99.41% of the stock is currently owned by institutional investors.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source